Prostatype Genomics AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was SEK 0.391687 million compared to SEK 0.26076 million a year ago. Revenue was SEK 0.391687 million compared to SEK 0.264058 million a year ago.

Net loss was SEK 7.81 million compared to SEK 5.56 million a year ago. Basic loss per share from continuing operations was SEK 0.34 compared to SEK 0.37 a year ago. Diluted loss per share from continuing operations was SEK 0.34 compared to SEK 0.37 a year ago.